ARGX — argenx
argenx (ARGX) — 2–3yr sleeve. VYVGART (efgartigimod) is an approved FcRn-targeting treatment franchise spanning generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), generating approximately $1.7 billion in global product sales in Q3 2026. The framework’s thesis rests on converting established FcRn leadership into a durable, multi-indication autoimmune franchise, supported by commercial expansion and growing financial strength.
Competitive context: UCB’s RYSTIGGO and Johnson & Johnson’s IMAAVY make FcRn an increasingly competitive market rather than a monopoly. Sleeve assignment remains 2–3yr pending a formal graduation reassessment, despite substantial commercial scale and growing revenue visibility.
Named risk: increasing FcRn competition and dependence on the VYVGART franchise could constrain long-duration growth and differentiation.
The BioCompound is a research publication. Nothing here constitutes investment advice.